Open AccessOverview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases
Author(s) -
Roger H. Kobayashi,
Jiří Litzman,
Syed Rizvi,
Huub T. C. Kreuwel,
Sonja Hoeller,
Sudhir Gupta
Publication year - 2022
Publication title -
immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.127
H-Index - 48
eISSN - 1750-7448
pISSN - 1750-743X
DOI - 10.2217/imt-2021-0313
Subject(s) - primary immunodeficiency , medicine , regimen , immunodeficiency , antibody , immunology , common variable immunodeficiency , intensive care medicine , immune system , surgery
Most primary immunodeficiency diseases, and select secondary immunodeficiency diseases, are treated with immunoglobulin (IG) therapy, administered intravenously or subcutaneously (SCIG). The first instance of IG replacement for primary immunodeficiency disease was a 16.5% formulation administered subcutaneously in 1952. While most SCIG products are now a 10 or 20% concentration, this review will focus on SCIG 16.5% products with a historical overview of development, including the early pioneers who initiated and refined IG replacement therapy, as well as key characteristics, manufacturing and clinical studies. In determining an appropriate IG regimen, one must consider specific patient needs, characteristics and preferences. There are advantages to SCIG, such as stable serum immunoglobulin G levels, high tolerability and the flexibility of self-administered home treatment.